《丙型肝炎病毒标志物检测与临床应用专家共识（2025年版）》解读

王慧; 王雅杰

doi:10.12449/JCH251209

《丙型肝炎病毒标志物检测与临床应用专家共识（2025年版）》解读

DOI: 10.12449/JCH251209

王慧,
王雅杰^, ,

传染病溯源预警与智能决策全国重点实验室，病毒性传染病研究北京市重点实验室，首都医科大学附属北京地坛医院检验科，北京 100015

基金项目:

北京市医院管理中心登峰人才培养计划 (DFL20241801)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：王慧负责撰写论文；王雅杰负责拟定写作思路，指导撰写文章并最终定稿。

详细信息

通信作者:
王雅杰， wangyajie@ccmu.edu.cn （ORCID： 0000-0002-3285-2537）

计量
- 文章访问数: 9
- HTML全文浏览量: 3
- PDF下载量: 9
- 被引次数: 0
出版历程
- 收稿日期: 2025-10-12
- 录用日期: 2025-10-16
- 出版日期: 2025-12-25

Interpretation of expert consensus on the detection and clinical application of hepatitis C virus markers （2025 edition）

Hui WANG,
Yajie WANG^{,
,}

National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases，Beijing Key Laboratory of Viral Infectious Diseases，Department of Clinical Laboratory，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Beijing Hospitals Authority's Ascent Plan (DFL20241801)

More Information

Corresponding author: WANG Yajie， wangyajie@ccmu.edu.cn （ORCID： 0000-0002-3285-2537）

摘要

摘要: 2025年，国家传染病医学中心临床检验联盟专家委员会组织国内专家联合编写了《丙型肝炎病毒标志物检测与临床应用专家共识（2025年版）》。该共识涵盖丙型肝炎防治目标、检测人群、检测标志物、检测方法及样本运输等内容，并结合我国感染现状及丙型肝炎检测标志物特点，提出了更加合理的检测策略。其重点在于弥补传统检测方法窗口期长、免疫缺陷人群漏检的不足，从而提升丙型肝炎的检出率，对于推动我国早日实现消除病毒性肝炎危害的目标，具有重要指导意义。本文对该共识进行解读，以期为临床丙型肝炎检测提供更加明确的实践参考。
- 丙型肝炎 /
- 标志物 /
- 诊疗准则（主题）
Abstract: In 2025， Expert Committee of the Clinical Laboratory Alliance， National Center for Infectious Diseases， organized related experts to develop Expert consensus on the detection and clinical application of hepatitis C virus markers （2025 edition）. This consensus outlines the objectives for hepatitis C prevention and control， identifies target populations for testing， and provides guidance on biomarkers， testing methods， and sample transportation. It also proposes optimized testing strategies tailored to the epidemiological characteristics of hepatitis C in China and the specific features of its diagnostic markers. The focus of this consensus is to address the shortcomings of traditional detection methods， such as prolonged window periods and missed diagnoses in immunocompromised populations， thereby improving the detection rate of hepatitis C. The consensus is of great importance for eliminating the public health threat of viral hepatitis in China. This article provides an interpretation of the consensus， in order to provide clearer practical guidance for the clinical testing of hepatitis C.
- Hepatitis C /
- Biomarker /
- Practice Guidelines as Topic

HTML全文

参考文献(25)

[1]	Expert Committee of the Clinical Laboratory Alliance, National Center for Infectious Diseases. Expert consensus on the detection and clinical application of hepatitis C virus markers(2025 edition)[J]. Chin J Lab Med, 2025, 48( 9): 1125- 1133. DOI: 10.3760/cma.j.cn114452-20250425-00253. 国家传染病医学中心临床检验联盟专家委员会. 丙型肝炎病毒标志物检测与临床应用专家共识(2025版)[J]. 中华检验医学杂志, 2025, 48( 9): 1125- 1133. DOI: 10.3760/cma.j.cn114452-20250425-00253.
[2]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Clin Infect Dis, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.
[3]	ROGER S, DUCANCELLE A, LE GUILLOU-GUILLEMETTE H, et al. HCV virology and diagnosis[J]. Clin Res Hepatol Gastroenterol, 2021, 45( 3): 101626. DOI: 10.1016/j.clinre.2021.101626.
[4]	World Health Organization. Global hepatitis report 2024[EB/OL].( 2024-04-09)[ 2025-01-02]. https://www.who.int/pu blications/i/item/97892400-91672. https: //www.who.int/pu blications/i/item/97892400-91672
[5]	National Disease Control and Prevention Administration. Overview of the epidemic situation of notifiable infectious diseases in China[EB/OL].( 2025-01-16)[ 2025-01-20]. https://www.ndcpa.gov.cn/jbkzzx/c100016/common/list.html. https: //www.ndcpa.gov.cn/jbkzzx/c100016/common/list.html 国家疾病预防控制局. 全国法定传染病疫情概况[EB/OL].( 2025-01-16)[ 2025-01-20]. https://www.ndcpa.gov.cn/jbkzzx/c100016/common/list.html. https: //www.ndcpa.gov.cn/jbkzzx/c100016/common/list.html
[6]	National Medical Quality Control Center for Infectious Diseases. Expert consensus on quality improvement of hepatitis C diagnosis and treatment[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2023, 17( 6): 385- 389. DOI: 10.3877/cma.j.issn.1674-1358.2023.06.005. 国家感染性疾病医疗质量控制中心. 丙型病毒性肝炎诊治质量改进专家共识[J/CD]. 中华实验和临床感染病杂志(电子版), 2023, 17( 6): 385- 389. DOI: 10.3877/cma.j.issn.1674-1358.2023.06.005.
[7]	China CDC. Technical Guidelines for Laboratory Testing of Hepatitis C Virus(2023 Revision)[S/OL].( 2023-10-16)[ 2025-01-03]. https://www.chinacdc.cn/zxdt/202310/t20231018_270168.html. https: //www.chinacdc.cn/zxdt/202310/t20231018_270168.html 中国疾病预防控制中心. 丙型肝炎病毒实验室检测技术规范(2023年修订版)[S/OL].( 2023-10-16)[ 2025-01-03]. https://www.chinacdc.cn/zxdt/202310/t20231018_270168.html. https: //www.chinacdc.cn/zxdt/202310/t20231018_270168.html
[8]	WANG YJ, CHEN Y, GUAN M, et al. National report on the current status and development needs of clinical laboratory testing for infectious diseases[J]. Chin J Lab Med, 2025, 48( 1): 38- 48. DOI: 10.3760/cma.j.cn114452-20240710-00363. 王雅杰, 陈瑜, 关明, 等. 全国传染病临床检验现状与发展需求调研报告[J]. 中华检验医学杂志, 2025, 48( 1): 38- 48. DOI: 10.3760/cma.j.cn114452-20240710-00363.
[9]	Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35( 12): 2670- 2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2670- 2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
[10]	World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: Updated version[EB/OL].( 2016-04-13)[ 2025-09-15]. https://www.who.int/publications/i/item/9789241549615. https: //www.who.int/publications/i/item/9789241549615
[11]	YANG RF, LIU N, BIAN CR, et al. A multi-center performance evaluation of different hepatitis C virus core antigen assays for clinical infection screening[J]. Chin J Lab Med, 2023, 46( 12): 1305- 1312. DOI: 10.3760/cma.j.cn114452-20230718-00014. 杨瑞锋, 刘宁, 卞成蓉, 等. 多种丙型肝炎病毒核心抗原试剂用于临床感染筛查的多中心性能评价[J]. 中华检验医学杂志, 2023, 46( 12): 1305- 1312. DOI: 10.3760/cma.j.cn114452-20230718-00014.
[12]	WANG YH, JIE W, LING J, et al. HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection[J]. Clin Lab Analy, 2021, 35( 6): e23755. DOI: 10.1002/jcla.23755.
[13]	CARTY PG, MCCARTHY M, O’NEILL SM, et al. Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy[J]. Rev Med Virol, 2022, 32( 4): e2320. DOI: 10.1002/rmv.2320.
[14]	JANCZEWSKA E, ZARĘBSKA-MICHALUK D, BERAK H, et al. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors-a multicenter cohort study[J]. BMC Infect Dis, 2018, 18( 1): 580. DOI: 10.1186/s12879-018-3465-2.
[15]	CHANG C, HUNG CH, WANG JH, et al. Hepatitis C core antigen highly correlated to HCV RNA[J]. Kaohsiung J Med Sci, 2018, 34( 12): 684- 688. DOI: 10.1016/j.kjms.2018.08.002.
[16]	THOMSON EC, NASTOULI E, MAIN J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV[J]. Aids, 2009, 23( 1): 89- 93. DOI: 10.1097/qad.0b013e32831940a3.
[17]	VAN TILBORG M, MARZOOQI SH AL, WONG WWL, et al. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: Retrospective screening and diagnostic cohort studies[J]. Lancet Gastroenterol Hepatol, 2018, 3( 12): 856- 864. DOI: 10.1016/s2468-1253(18)30271-1.
[18]	ADLAND E, JESUTHASAN G, DOWNS L, et al. Hepatitis virus(HCV) diagnosis and access to treatment in a UK cohort[J]. BMC Infect Dis, 2018, 18( 1): 461. DOI: 10.1186/s12879-018-3367-3.
[19]	PROSTKO J, ROTHMAN R, HSIEH YH, et al. Performance evaluation of the Abbott Alinity Hepatitis C antigen next assay in a US urban emergency department population[J]. J Clin Virol, 2024, 175: 105743. DOI: 10.1016/j.jcv.2024.105743.
[20]	ROCKSTROH JK, FELD JJ, CHEVALIEZ S, et al. HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients[J]. J Virol Meth, 2017, 245: 14- 18. DOI: 10.1016/j.jviromet.2017.03.002.
[21]	LIN SF, TUNG SY, WEI KL, et al. Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C[J]. PLoS One, 2020, 15( 3): e0229994. DOI: 10.1371/journal.pone.0229994.
[22]	ZHANG YQ, WANG J, CHANG JX, et al. Correlation and the clinical significance of hepatitis C virus RNA and hepatitis C core antigen[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2019, 13( 3): 185- 189. DOI: 10.3877//cma.j.issn.1674-1358.2019.03.003. 张怡青, 王洁, 常静霞, 等. 丙型肝炎病毒RNA与核心抗原的相关性及其临床意义[J/CD]. 中华实验和临床感染病杂志(电子版), 2019, 13( 3): 185- 189. DOI: 10.3877//cma.j.issn.1674-1358.2019.03.003.
[23]	HANSOONGNERN P, PRATEDRAT P, NILYANIMIT P, et al. An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA[J]. PLoS One, 2023, 18( 6): e0287694. DOI: 10.1371/journal.pone.0287694.
[24]	FENG B, YANG RF, JIANG HJ, et al. Correlation analysis of hepatitis C virus core antigen and low viral loads: Can core antigen replace nucleic acid test?[J]. Clin Exp Med, 2020, 20( 1): 131- 141. DOI: 10.1007/s10238-019-00588-1.
[25]	ORGANIZATION WH. WHO guidelines for malaria, 30 November 2024[M]. World Health Organization, 2024. DOI: 10.2471/b09146.